Sun Pharmaceutical Industries is cutting staff after the $3.2 billion acquisition of Ranbaxy Laboratories.

The focus is R&D staff, an additional cut that comes a month after about 150 senior executives were let go.

Nearly 15 employees from the R&D department are to exit as Sun integrates a combined staff base of 30,000.